CROI 2021: New compounds for prevention and treatment of COVID-19

1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19, CROI 28 (virtual) 2021.

Simon Collins, HIV i-Base

CROI 2021 included important results from experimental treatments that reported positive results from early interventions, especially using monoclonal antibodies. Four short reports are included below.

• Molnupiravir significantly reduced SARS-CoV-2 viral load after five days in early infection
• Bamlanivimab works as prophylaxis in high risk populations
• Bamlanivimab and etesevimab (Eli-Lilly) reduced hospitalisation and mortality in mild/moderate infection
• Casirivimab and imdevimab (Regeneron) dual mAbs reduce risk of symptomatic transmission

This report was first published on 19 March 2021.